Javascript must be enabled to continue!
A STUDY OF ECHOCARDIOGRAPHIC CHANGES IN PATIENTS WITH CIRRHOSIS OF LIVER
View through CrossRef
Background/Aims: Cirrhosis is associated with a significant number of cardiac abnormalities but, the information available is scanty about the changes associated with it in India. Which include increased cardiac output, increased wall thickness of cardiac chambers, left ventricular diastolic dysfunction, and PAH. These cardiac abnormalities in patients with Cirrhosis have been termed as Cirrhotic Cardiomyopathy. Cirrhotic Cardiomyopathy may be a significant cause of morbidity and mortality in patients with Cirrhosis. With the advent of increased liver transplantation in India, this entity may have an impact on transplantation success. The present study aims to evaluate the cardiac abnormalities in patients with cirrhosis using 2D Echocardiography to detect the occurrence of LV dysfunction, pulmonary hypertension, pericardial effusion, and to assess the contribution of cardiac dysfunction on mortality, if any. Methodology: Thirty patients with Cirrhosis (alcoholic and non-alcoholic) were enrolled. Thirty age and sex-matched controls without cardiovascular disease were included for comparison. Data collection was done by clinical history taking, examination, and investigations. All subjects underwent Echo study was at 0, 6 and12 months and controls at the start of the study. Observations and Results: 1. The mean age of study group was 54.5 ± 15 yrs among them, males constituted 93 % of the study population, the majority of patients were in Child class B (43.3%), and Child A (40%). None of the study population died during follow up. 2. The salient Echocardiographic abnormalities noted in the study population were a) Interventricular septal thickness showed significant change compared to control (9.80 ± 1.06 vs. 8.00 ± 1.00mm mm). b) Doppler echocardiography detected elevated pulmonary arterial pressure (PAP) in the study population compared to control (20.73 ±2.43mm Hg vs.18.26 ± 2.1mm Hg). c) Diastolic dysfunction occurred in the form of increased Deceleration time (223.17 ± 13.93 ms vs. 190.83 ± 14.0ms) and increased E: A ratio (1.10±0.1 vs. 1.04±0.12) was noted in subjects with Cirrhosis. Two of the study subjects had pericardial effusion. (6.7%) 3. There is no evidence of systolic dysfunction noted in the study population. 4. There is no correlation between the severity of Cirrhosis and echocardiographic changes. 5. There were no differences in echo parameters among patients with alcoholic or non-alcoholic etiology of Cirrhosis. 6. There was no fatality recorded due to cardiac dysfunction Conclusion: 1. This study demonstrates that Indian patients with cirrhosis do have diastolic dysfunction. In the absence of other cardiac disease risk factors, this dysfunction can be attributed only to cirrhotic cardiomyopathy. 2. Echocardiography plays a significant role in detecting early cardiac changes in cirrhosis however, these changes do not seem to be a predictor of increased mortality in cirrhosis patients.
International Journal Of Advanced Research
Title: A STUDY OF ECHOCARDIOGRAPHIC CHANGES IN PATIENTS WITH CIRRHOSIS OF LIVER
Description:
Background/Aims: Cirrhosis is associated with a significant number of cardiac abnormalities but, the information available is scanty about the changes associated with it in India.
Which include increased cardiac output, increased wall thickness of cardiac chambers, left ventricular diastolic dysfunction, and PAH.
These cardiac abnormalities in patients with Cirrhosis have been termed as Cirrhotic Cardiomyopathy.
Cirrhotic Cardiomyopathy may be a significant cause of morbidity and mortality in patients with Cirrhosis.
With the advent of increased liver transplantation in India, this entity may have an impact on transplantation success.
The present study aims to evaluate the cardiac abnormalities in patients with cirrhosis using 2D Echocardiography to detect the occurrence of LV dysfunction, pulmonary hypertension, pericardial effusion, and to assess the contribution of cardiac dysfunction on mortality, if any.
Methodology: Thirty patients with Cirrhosis (alcoholic and non-alcoholic) were enrolled.
Thirty age and sex-matched controls without cardiovascular disease were included for comparison.
Data collection was done by clinical history taking, examination, and investigations.
All subjects underwent Echo study was at 0, 6 and12 months and controls at the start of the study.
Observations and Results: 1.
The mean age of study group was 54.
5 ± 15 yrs among them, males constituted 93 % of the study population, the majority of patients were in Child class B (43.
3%), and Child A (40%).
None of the study population died during follow up.
2.
The salient Echocardiographic abnormalities noted in the study population were a) Interventricular septal thickness showed significant change compared to control (9.
80 ± 1.
06 vs.
8.
00 ± 1.
00mm mm).
b) Doppler echocardiography detected elevated pulmonary arterial pressure (PAP) in the study population compared to control (20.
73 ±2.
43mm Hg vs.
18.
26 ± 2.
1mm Hg).
c) Diastolic dysfunction occurred in the form of increased Deceleration time (223.
17 ± 13.
93 ms vs.
190.
83 ± 14.
0ms) and increased E: A ratio (1.
10±0.
1 vs.
1.
04±0.
12) was noted in subjects with Cirrhosis.
Two of the study subjects had pericardial effusion.
(6.
7%) 3.
There is no evidence of systolic dysfunction noted in the study population.
4.
There is no correlation between the severity of Cirrhosis and echocardiographic changes.
5.
There were no differences in echo parameters among patients with alcoholic or non-alcoholic etiology of Cirrhosis.
6.
There was no fatality recorded due to cardiac dysfunction Conclusion: 1.
This study demonstrates that Indian patients with cirrhosis do have diastolic dysfunction.
In the absence of other cardiac disease risk factors, this dysfunction can be attributed only to cirrhotic cardiomyopathy.
2.
Echocardiography plays a significant role in detecting early cardiac changes in cirrhosis however, these changes do not seem to be a predictor of increased mortality in cirrhosis patients.
Related Results
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Sexual Dysfunction In Cirrhosis: A Prospective Multicenter Study
Sexual Dysfunction In Cirrhosis: A Prospective Multicenter Study
Introduction: All the manifestations of cirrhosis, sexual dysfunction, mainly because of its taboo nature. The least sought after by hepatologists and the least reported spontaneou...
Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma
Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma
Abstract
Background
About 20% of patients infected with SARS-CoV-2 develop COVID-19—the disease that has dominated health care in the last two years...
Echocardiographic features, mortality, and adrenal function in patients with cirrhosis and septic shock
Echocardiographic features, mortality, and adrenal function in patients with cirrhosis and septic shock
Objectives: Cirrhosis of the liver is associated with an increased susceptibility to bacterial infections capable of causing septic shock and with a basal hyperdynamic circulatory...
Ursodeoxycholic acid therapy in primary biliary cirrhosis
Ursodeoxycholic acid therapy in primary biliary cirrhosis
Background/Aims:
A double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) was conducted in 180 patients with primary biliary cirrhosis (PBC) to define th...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Etiologies of Liver Cirrhosis and Their Clinical Presentation among Inpatients in Medical City Complex - Baghdad Teaching Hospital
Etiologies of Liver Cirrhosis and Their Clinical Presentation among Inpatients in Medical City Complex - Baghdad Teaching Hospital
BACKGROUND: Liver cirrhosis is one of common diseases that doctors deal with during working days, so it is important for all doctors to have a basic knowledge about its etiologies,...

